Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi)

Figure 1

Absolute neutrophil count (ANC), hemoglobin (Hgb), and platelet counts throughout mivebresib mono- or combination therapy with venetoclax. ANC was less than 100/μL during days 1 to 84, corresponding to cycles 1 to 3 of monotherapy (as denoted by grey triangle), and recovered to greater than 1,000/μL, thereafter. Hgb generally remained between 7 and 12 g/dL throughout all treatment modalities. Platelets remained less than 10,000/μL between days 140 and 190, corresponding to cycles 4 and 6 of monotherapy (as denoted by black oval), and then increased to 15,000 to 120,000/μL for the duration of the trial. M = mivebresib; V = venetoclax; E = eltrombopag.